Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Trial ID # NCT02766582
Phase II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Carboplatin, Paclitaxel, Pembrolizumab
Eligible Participant

Stage III–IV epithelial ovarian cancer with residual disease after cytoreductive surgery

Patients Enrolled

28

Therapy Setting

First-line

Study Design

Open-Label, Non-randomized

Endpoints

PFS, evaluated per RECIST

Efficacy

PFS (6 months): 82%
PFS (9 months): 77%
PFS (12 months): 59%

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: neutropenia (67%), anemia (25%), respiratory (10%)

Conclusion

Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising

Reference

Uyar D et al. Preliminary results from phase II trial of pembrolizumab with first line platinum based chemotherapy followed by maintenance pembrolizumab for patients with suboptimally cytoreduced advanced epithelial ovarian cancer. SGO (2020) abstract 314
https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/15969